

Irritable Bowel Syndrome (IBS) Treatment Market Size, Share And Growth Analysis For 2024-2033

The Business Research Company's Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024 – Market Size, Trends. And Global Forecast 2024-2033

LANDON, GREATER LANDON, UK, June 17, 2024 /EINPresswire.com/ -- The irritable bowel syndrome (IBS) treatment market is projected to grow from \$2.5 billion in 2023 to \$2.77 billion in 2024, at a CAGR of 10.8%. The



market is anticipated to reach \$4.29 billion by 2028, driven by advancements in patient-centric healthcare models and digital health solutions.

Aging Population Drives Market Growth



The irritable bowel syndrome (ibs) treatment market size is expected to see rapid growth in the next few years. It will grow to \$4.29 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%."

The Business Research Company The aging population is a significant factor contributing to the growth of the IBS treatment market. With a growing proportion of elderly individuals, there is an increased need for managing gastrointestinal symptoms associated with aging. According to the World Health Organization, the population of people aged 60 years and older is expected to double by 2050, reaching 2.1 billion. This demographic shift is driving the demand for effective IBS treatments to enhance digestive health and overall wellbeing.

Explore comprehensive insights into the IBS treatment market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=11978&type=smp

Major Players and Market Trends

Major companies in the IBS treatment market include Pfizer Inc., Johnson & Johnson Services

Inc., AbbVie Inc., Novartis AG, and AstraZeneca PLC. These companies are focusing on product innovations to strengthen their market positions. For instance, in April 2022, Ardelyx launched IBSRELA, a first-in-class treatment for IBS-C in adults. This NHE3 inhibitor is the first novel mechanism therapy for IBS-C developed in almost ten years, offering a new treatment option for symptoms like constipation, bloating, and stomach pain.

Segments:

- · By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
- By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
- By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
- By End-Users: Hospitals, Clinics, Homecare Settings

Geographical Insights: North America Leading the Market

North America was the largest region in the IBS treatment market in 2023. Europe is expected to be the fastest-growing region during the forecast period. The comprehensive report provides detailed insights into regional dynamics, market trends, and growth opportunities. Access the complete report for an in-depth analysis of the IBS treatment market: https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

<u>Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024</u> from TBRC covers the following information:

- Market size date for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on irritable bowel syndrome (ibs) treatment market size, irritable bowel syndrome (ibs) treatment market drivers and trends, irritable bowel syndrome (ibs) treatment market major players, competitors' revenues, market positioning, and market growth across geographies. The irritable bowel syndrome (ibs) treatment market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By <u>The Business Research Company:</u>
DNA Diagnostics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dna-diagnostics-global-market-report

Medical X-Ray Equipment And Imaging Software Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/medical-x-ray-equipment-and-imaging-software-global-market-report

Pharmacy Automation Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmacy-automation-global-market-report

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc info

Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/720616284

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.